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Pancreatic neuroendocrine tumours (pNETS) are a part
of a heterogeneous group of tumors, neuroendocrine
gastroenteropancreatic tumors (GEP-NETs), with their
origin in neuroendocrine cells of the embryological gut.
Most commonly, primary lesions are located in gastric
mucosa, small and large intestine, rectum and pancreas.
The overall incidence of all GEP-NETS has increased
over the past decade, with pNET incidence of 0.32/100
000/year. Patients with multiple endocrine neoplasia
type 1 (MEN-1) or von Hippel–Lindau’s disease (VHL),
have pNETS 15–20 years earlier than patients with
sporadic pNETS [1].
CT and MRI are typically the first line imaging modal-
ities of choice in the evaluation of most patients with sus-
pected pNETS. The role of cross sectional imaging is
complementary to somatostatin receptor based imaging
and PET CT. CT and MRI are essential in the detection of
primary tumours, which is challenging in small secretory
insulinomas and gastrinomas. Meticulous care must be
taken in cross sectional imaging technique to maximize
the sensitivity for detection of the small and frequently
multiple lesions. CT imaging should include triphasic ima-
ging. No one sequence detects all pNETS on MRI and
multiple sequences including T1, T2, fat saturated images
are required. Over the last few years the use of diffusion
weighted imaging (DWI) has also improved primary lesion
detection in the pancreas [2] and detection of small meta-
static liver and bone lesions.
Surgery is the only curative treatment for pNETS . The
role of CT and MRI also extends to staging and planning
surgical resection. Excellent anatomical detail can be
accurately provided with CT and multi-planar and thin
section imaging. The staging for pNETS is based on
recommendations from European Neuroendocrine
Tumour Society [3] and WHO staging which will be
outlined with imaging and pathological illustrations.
Larger pNETS, usually have low or no secretory activity
and characteristic features on CT and MRI, which provide
an indication to their histopathology. Punctate calcifica-
tions, lack of biliary obstruction and vascular invasion
despite large tumour volume are features that allow the
radiologist to make the initial working diagnosis of a
pNET. In these patients the role of imaging is to provide
tissue diagnosis and staging by biopsy, assess tumour bulk,
detect distant metastases and assess disease response
following therapy.
A large number, close to 50%, of non-secretory pNETS
present with distant disease. These are offered radiola-
belled therapies but increasingly radiological embolization
techniques and radiofrequency is available for local con-
trol. Targeted therapies with vascular endothelial growth
factor receptor-tyrosine kinase inhibitor (VEGFr-TKI),
Sunitanib and the mammalian target of rapamycin
(mTOR) inhibitor, Everolimus for medical management of
locally advanced and metastatic disease sees the role of
CT and MRI now extending to evaluation of disease
response in phase II and III trials. The imaging techniques
again require scan phase precision and consistency to
ensure accuracy for tumour response assessment which is
based on RECIST criteria.
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